NCT03848663 Visual Remapping to Aid Reading With Field Loss
| NCT ID | NCT03848663 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Minnesota |
| Condition | Age-related Macular Degeneration |
| Study Type | INTERVENTIONAL |
| Enrollment | 108 participants |
| Start Date | 2022-02-01 |
| Primary Completion | 2026-07-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 108 participants in total. It began in 2022-02-01 with a primary completion date of 2026-07-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Reading performance in patients with Central Vision Loss and age matched controls with artificial scotomas will be measured with and without different kinds of remapping of missing text to different parts of the visual field.
Eligibility Criteria
Inclusion Criteria: 1. 16 years or older 2. Central vision loss of at least 5 deg diameter, including the fovea, from bilateral central scotomas 3. Stable fixation (+/- 1 deg) using their PRL. 4. No cognitive impairment as indicated by a Mini-Mental State Examination (MMSE). 5. Satisfactory calibration achievable using eye tracker Exclusion Criteria: 1. Central vision loss of less than 5 deg diameter; scotomas that do not cover the fovea; unilateral scotomas 2. Poor fixation (worse than+/- 1 deg) using their PRL. 3. Cognitive impairment as indicated by a Mini-Mental State Examination (MMSE). 4. Satisfactory calibration not achievable using eye tracker
Contact & Investigator
Stephen Engel, Ph.D.
PRINCIPAL INVESTIGATOR
University of Minnesota
Frequently Asked Questions
Who can join the NCT03848663 clinical trial?
This trial is open to participants of all sexes, aged 16 Years or older, studying Age-related Macular Degeneration. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03848663 currently recruiting?
Yes, NCT03848663 is actively recruiting participants. Contact the research team at engel@umn.edu for enrollment information.
Where is the NCT03848663 trial being conducted?
This trial is being conducted at Minneapolis, United States.
Who is sponsoring the NCT03848663 clinical trial?
NCT03848663 is sponsored by University of Minnesota. The principal investigator is Stephen Engel, Ph.D. at University of Minnesota. The trial plans to enroll 108 participants.